These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 34191697)

  • 1. Neurological Effects of SARS-CoV-2 and Neurotoxicity of Antiviral Drugs Against COVID-19.
    Ünlü B; Simsek R; Köse SBE; Yirün A; Erkekoglu P
    Mini Rev Med Chem; 2022; 22(2):213-231. PubMed ID: 34191697
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic.
    Vlachakis D; Papakonstantinou E; Mitsis T; Pierouli K; Diakou I; Chrousos G; Bacopoulou F
    Food Chem Toxicol; 2020 Dec; 146():111805. PubMed ID: 33038452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recent Developments on Therapeutic and Diagnostic Approaches for COVID-19.
    Majumder J; Minko T
    AAPS J; 2021 Jan; 23(1):14. PubMed ID: 33400058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Measures for the Novel Coronavirus: A Review of Current Status and Future Perspective.
    Shahverdi M; Darvish M
    Curr Mol Med; 2021; 21(7):562-572. PubMed ID: 33272178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Review on Screening Models for Potential Therapeutic Candidates and Targets Against SARS-CoV-2.
    Das M; Kumar M; Jha A; Madhukiran DR; Bharti K; Mondal S; Mishra B
    Curr Drug Targets; 2021; 22(11):1232-1254. PubMed ID: 33371846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic targets and potential agents for the treatment of COVID-19.
    Wu Y; Li Z; Zhao YS; Huang YY; Jiang MY; Luo HB
    Med Res Rev; 2021 May; 41(3):1775-1797. PubMed ID: 33393116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The emergence of a novel coronavirus (SARS-CoV-2) disease and their neuroinvasive propensity may affect in COVID-19 patients.
    Yashavantha Rao HC; Jayabaskaran C
    J Med Virol; 2020 Jul; 92(7):786-790. PubMed ID: 32320066
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Review on Remdesivir: A Broad-spectrum Antiviral Molecule for Possible COVID-19 Treatment.
    Khazir J; Maqbool T; Mir BA
    Mini Rev Med Chem; 2021; 21(17):2530-2543. PubMed ID: 33596800
    [TBL] [Abstract][Full Text] [Related]  

  • 9. COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.
    Aljabali AAA; Bakshi HA; Satija S; Metha M; Prasher P; Ennab RM; Chellappan DK; Gupta G; Negi P; Goyal R; Sharma A; Mishra V; Dureja H; Dua K; Tambuwala MM
    Pharm Nanotechnol; 2020; 8(4):323-353. PubMed ID: 32811406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic Attempts Towards Eminent Anti-viral Candidates of SARS-CoV.
    Kundu S; Sarkar D
    Mini Rev Med Chem; 2022; 22(2):232-247. PubMed ID: 34254915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective.
    Bolarin JA; Oluwatoyosi MA; Orege JI; Ayeni EA; Ibrahim YA; Adeyemi SB; Tiamiyu BB; Gbadegesin LA; Akinyemi TO; Odoh CK; Umeobi HI; Adeoye AB
    Int Immunopharmacol; 2021 Jan; 90():107228. PubMed ID: 33302035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. COVID-19 diagnosis and management: a comprehensive review.
    Pascarella G; Strumia A; Piliego C; Bruno F; Del Buono R; Costa F; Scarlata S; Agrò FE
    J Intern Med; 2020 Aug; 288(2):192-206. PubMed ID: 32348588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SARS-CoV-2 multifaceted interaction with human host. Part I: What we have learnt and done so far, and the still unknown realities.
    Delcuve GP; Lakowski TM; Su RC; Beacon TH; Davie JR
    IUBMB Life; 2020 Nov; 72(11):2313-2330. PubMed ID: 32918855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repositioning of Drugs to Counter COVID-19 Pandemic - An Insight.
    Akilesh SM; J R; Palanisamy D; Wadhwani A
    Curr Pharm Biotechnol; 2021; 22(2):192-199. PubMed ID: 32867651
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elucidating the Drug Repurposing Spectra of COVID-19 with its Analogues SARS and MERS.
    Mishra J; Prasun C; Sahoo PK; Nair MS
    Mini Rev Med Chem; 2021; 21(20):3191-3202. PubMed ID: 33632095
    [TBL] [Abstract][Full Text] [Related]  

  • 16. COVID-19: morphology and mechanism of the SARS-CoV-2, global outbreak, medication, vaccines and future of the virus.
    Bhattacharyya P; Das S; Aich S; Sarkar J
    Front Biosci (Elite Ed); 2021 Dec; 13(2):272-290. PubMed ID: 34937314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cysteamine with In Vitro Antiviral Activity and Immunomodulatory Effects Has the Potential to Be a Repurposing Drug Candidate for COVID-19 Therapy.
    Alonzi T; Aiello A; Petrone L; Najafi Fard S; D'Eletto M; Falasca L; Nardacci R; Rossin F; Delogu G; Castilletti C; Capobianchi MR; Ippolito G; Piacentini M; Goletti D
    Cells; 2021 Dec; 11(1):. PubMed ID: 35011614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathogenetic profiling of COVID-19 and SARS-like viruses.
    Nain Z; Rana HK; Liò P; Islam SMS; Summers MA; Moni MA
    Brief Bioinform; 2021 Mar; 22(2):1175-1196. PubMed ID: 32778874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Comprehensive Review of COVID-19 Virology, Vaccines, Variants, and Therapeutics.
    Forchette L; Sebastian W; Liu T
    Curr Med Sci; 2021 Dec; 41(6):1037-1051. PubMed ID: 34241776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Two years into COVID-19 - Lessons in SARS-CoV-2 and a perspective from papers in FEBS Letters.
    Greber UF
    FEBS Lett; 2021 Dec; 595(23):2847-2853. PubMed ID: 34787897
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.